Want to see HK:8225 full AI Analyst Report?
China Health Group Inc. (8225) AI Stock Analysis
China Health Group Inc.
(HKEX:8225)
Low financial performance due to revenue volatility and sustained losses is the primary driver, compounded by negative valuation metrics and bearish technical indicators.
China Health Group Inc. (8225) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 65.69M
- Dividend Yield
- ―
- Average Volume (3M)
- 243.28K
- Price to Earnings (P/E)
- -2.6
- Beta (1Y)
- 0.24
- Revenue Growth
- 5.27%
- EPS Growth
- -4.86%
- Country
- Hong Kong
- Employees
- 33
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
China Health Group Inc. Business Overview & Revenue Model
Company Description
China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China. The company offers contracted pharmaceutical development and clinical research, an...
China Health Group Inc. Financial Statement Overview
Summary
Revenue volatility with sharp declines and persistent losses since 2022; shrinking assets and equity but supported by debt-free balance sheet and improving cash flows.
Income Statement
25NegativeBalance Sheet
30NegativeCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.92M | 27.82M | 26.45M | 21.43M | 13.09M | 83.60M |
| Gross Profit | 17.58M | 15.97M | 10.07M | 8.21M | 5.74M | 63.86M |
| EBITDA | -2.66M | -14.05M | -14.24M | -57.98M | -15.66M | 42.74M |
| Net Income | -14.57M | -14.57M | -14.52M | -58.01M | -15.84M | 36.33M |
Balance Sheet | ||||||
| Total Assets | 87.11M | 87.11M | 100.96M | 119.35M | 178.63M | 194.32M |
| Cash, Cash Equivalents and Short-Term Investments | 25.16M | 25.16M | 15.89M | 7.30M | 12.07M | 17.02M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 32.33M | 32.33M | 31.24M | 35.17M | 36.74M | 42.54M |
| Stockholders Equity | 55.41M | 55.41M | 70.35M | 84.82M | 142.32M | 155.57M |
Cash Flow | ||||||
| Free Cash Flow | 7.58M | 9.02M | 8.52M | -4.88M | -5.16M | -10.28M |
| Operating Cash Flow | 7.59M | 9.03M | 10.28M | 1.12M | -5.16M | -10.28M |
| Investing Cash Flow | 35.00K | -34.09K | -230.00K | -1.04M | -2.15M | 6.96M |
| Financing Cash Flow | 0 | 0 | 0 | 0 | 0 | -1.51M |
China Health Group Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8225, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.08, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 30.31 is Neutral, neither overbought nor oversold. The STOCH value of 21.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8225.
China Health Group Inc. Peers Comparison
Overall Rating
HK:235975Outperform
HK:612760Neutral
HK:334755Neutral
HK:666754Neutral- HK:822538Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2359 | 75Outperform | HKD 506.60B | 15.47 | 30.77% | 1.29% | 38.26% | 84.56% |
| HK:6127 | 60Neutral | HKD 36.16B | 29.06 | 13.10% | 0.60% | 16.68% | 442.43% |
| HK:3347 | 55Neutral | HKD 42.54B | -103.48 | -2.00% | 0.38% | 21.72% | -169.67% |
| HK:6667 | 54Neutral | HKD 1.59B | 50.39 | 4.04% | 2.40% | 169.02% | -24.61% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:8225 | 38Underperform | HKD 65.69M | -2.60 | -15.01% | ― | 5.27% | -4.86% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:8225 | China Health Group Inc. | 0.07 | -0.09 | -58.23% | |
| HK:3347 | Hangzhou Tigermed Consulting Co., Ltd. Class H | 37.92 | -8.52 | -18.35% | |
| HK:2359 | WuXi AppTec Co., Ltd. Class H | 185.40 | 83.35 | 81.67% | |
| HK:6127 | JOINN Laboratories (China) Co., Ltd. Class H | 22.88 | 2.30 | 11.20% | |
| HK:6667 | Mega Genomics Limited | 7.08 | 0.05 | 0.68% | |
| HK:8247 | Biosino Bio-Technology & Science, Inc. Class H | 2.98 | 2.19 | 276.58% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026